BEIJING – Zhongshan-based Akeso Inc., which focuses on bispecific antibodies, is again seeking pre-revenue listing on the Hong Kong Stock Exchange (HKEX), after its first IPO attempt failed to go through in December. The move comes at a time when analysts believe the coronavirus outbreak is weighing on the city’s IPO market.
DUBLIN – Azafaros BV raised €25 million (US$27.5 million) to develop orally available azasugar drugs with potential application to multiple lysosomal storage diseases.
DUBLIN – Maat Pharma SA closed an €18 million (US$19.9 million) series B round to continue development of its standardized, off-the-shelf fecal microbiota transplant (FMT) therapy, MaaT-013.
Investors in small and midsized biopharma companies were certainly rewarded in 2019, with group members in the BioWorld Drug Developers index on a tear. The price-weighted index returned 40% in value thanks to a steady flow of positive regulatory and clinical trial results from the companies throughout the year. However, investors may be less impressed with the start they have made this year, with the index dipping 8.4% in January.
Biopharmas raising money in public or private financings, including: Albireo, Arch Biopartners, Biontech, Black Diamond, Integra, Juvise, Kali-Extracts, Rockwell, Valneva.
RSS
